Pfizer pours $25m into Vedanta's Phase II IBD study
Pfizer pours $25m into Vedanta's Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II study of VE202 to treat inflammatory bowel disease (IBD), scheduled to launch in 2021. A Vedanta spok...